Segment & Geographic Data
Quant-Grade Normalized (live API)
API & CSV Delivery
Biospecifics Technologies's Business Segments
Biospecifics Technologies's reported revenue by business segment and by geographic region, quarterly and annual, normalized against the consolidated income statement. Free below: the top 3 rows per table, this quarter and this fiscal year. Subscriber access adds the full segment history and operating income by segment.
Reportable Segments
-
Largest Segment
-
Total Revenue
$ 11
Regions Reported
-
Revenue by Product & Service Category -
- Royalty82.2%
- License17.8%
Revenue by Product & Service Category -
| Category | Revenue (Millions) | % of Total |
|---|---|---|
| Royalty | $ 9 | 82.2% |
| License | $ 2 | 17.8% |
Product and service categories are a supplemental disclosure and are not required to sum to consolidated revenue or to the reportable segments above.
Description of Biospecifics Technologies
Biospecifics Technologies Corp is a biopharmaceutical company that specializes in the development and commercialization of collagenase-based therapies for the treatment of various medical conditions. The company's core technology is based on the use of enzymes that selectively break down collagen, a protein that is a major component of connective tissues in the body.
Biospecifics Technologies Corp was founded in 1990 and its headquarters are located in Lynbrook, New York. The company is publicly traded on NASDAQ with the ticker symbol "BSTC".
The company's lead product is Xiaflex, a collagenase-based therapy that is FDA-approved for the treatment of Dupuytren's contracture, a condition that causes the fingers to curl inward towards the palm. Xiaflex is also FDA-approved for the treatment of Peyronie's disease, a connective tissue disorder that affects the penis.
In addition to Xiaflex, Biospecifics Technologies Corp is also developing collagenase-based therapies for the treatment of other conditions, including cellulite, frozen shoulder syndrome, and lipomas.
The company has a strong pipeline of products in development, including CCH for the treatment of cellulite and injectable collagenase for the treatment of Dupuytren's contracture.
Biospecifics Technologies Corp has a strong intellectual property portfolio, with numerous patents and patent applications relating to its collagenase-based technologies. The company has also entered into licensing agreements with several major pharmaceutical companies for the development and commercialization of its products.
Furthermore, the company has a proven track record of success with Xiaflex. In 2019, the company reported revenues of $119.5 million, a 19% increase from the previous year, driven by increased sales of Xiaflex.
Overall, Biospecifics Technologies Corp is a leading biopharmaceutical company with a strong focus on collagenase-based therapies. The company has a strong pipeline of products in development and a proven track record of success with Xiaflex. With a strong intellectual property portfolio and a growing market for its products, Biospecifics Technologies Corp is well-positioned for future growth and success in the biopharmaceutical industry.
Biospecifics Technologies Corp was founded in 1990 and its headquarters are located in Lynbrook, New York. The company is publicly traded on NASDAQ with the ticker symbol "BSTC".
The company's lead product is Xiaflex, a collagenase-based therapy that is FDA-approved for the treatment of Dupuytren's contracture, a condition that causes the fingers to curl inward towards the palm. Xiaflex is also FDA-approved for the treatment of Peyronie's disease, a connective tissue disorder that affects the penis.
In addition to Xiaflex, Biospecifics Technologies Corp is also developing collagenase-based therapies for the treatment of other conditions, including cellulite, frozen shoulder syndrome, and lipomas.
The company has a strong pipeline of products in development, including CCH for the treatment of cellulite and injectable collagenase for the treatment of Dupuytren's contracture.
Biospecifics Technologies Corp has a strong intellectual property portfolio, with numerous patents and patent applications relating to its collagenase-based technologies. The company has also entered into licensing agreements with several major pharmaceutical companies for the development and commercialization of its products.
Furthermore, the company has a proven track record of success with Xiaflex. In 2019, the company reported revenues of $119.5 million, a 19% increase from the previous year, driven by increased sales of Xiaflex.
Overall, Biospecifics Technologies Corp is a leading biopharmaceutical company with a strong focus on collagenase-based therapies. The company has a strong pipeline of products in development and a proven track record of success with Xiaflex. With a strong intellectual property portfolio and a growing market for its products, Biospecifics Technologies Corp is well-positioned for future growth and success in the biopharmaceutical industry.
Biospecifics Technologies Corp is a biopharmaceutical company that specializes in developing innovative injectable collagenase-based therapies targeting a variety of medical conditions. The companys offerings can be segmented into three main categories: medical/pharmaceutical products, licensing and collaborations, and research and development.
1. Medical / Pharmaceutical Products
At the forefront of Biospecifics Technologies Corps product lineup is XIAFLEX. This injectable collagenase enzyme represents a groundbreaking advance in the treatment of several conditions characterized by excessive collagen buildup. XIAFLEX acts by breaking down collagen, leading to tissue release and improved mobility in affected areas. Its key indications include:
- Dupuytrens Contracture: A hand condition that leads to the thickening and shortening of connective tissues, resulting in the fingers bending towards the palm, which can significantly hinder hand function. XIAFLEX works by enzymatically targeting and disrupting the collagen strands, allowing the fingers to be straightened.
- Peyronie’s Disease: A condition that results in the formation of fibrous scar tissue within the penis, causing curved, painful erections. XIAFLEX is administered via injection directly into the scar tissue, facilitating collagen breakdown and improving penile curvature and function.
- Cellulite: XIAFLEX is also employed in treating cellulite, a condition characterized by lumpy, dimpled skin, particularly on the thighs and buttocks. The injectable collagenase targets the fibrous bands beneath the skin, softening and releasing the tension, leading to smoother skin appearance.
In addition to XIAFLEX, Biospecifics Technologies Corp is actively engaged in the development of other collagenase-based therapies for additional conditions, including:
- Uterine Fibroids: These benign tumors of the uterus can cause pain and heavy menstrual bleeding. The company is exploring collagenase applications to alleviate symptoms and reduce the size of fibroids non-surgically.
- Adhesive Capsulitis (Frozen Shoulder): This painful condition restricts the shoulders range of motion. Research is underway to utilize collagenase injections to release the tight, thickened tissue surrounding the shoulder joint, providing pain relief and restoring mobility.
- Lipomas: Non-cancerous tumors composed of fat tissue that can be painful or bothersome. The application of collagenase has the potential to non-invasively diminish these growths.
Licensing and Collaborations
Biospecifics Technologies Corp is open to forming partnerships with other pharmaceutical companies and organizations that wish to leverage its expertise in collagenase-based therapies. Through licensing agreements, they provide their advanced drug development, clinical trial management, and regulatory experience to potential collaborators. This strategic collaboration model helps expand the reach of their innovative therapies and promotes the development of new applications addressing unmet medical needs.
Research and Development
Recognizing the changing landscape of medicine and the ongoing need for novel therapies, Biospecifics Technologies Corp is heavily invested in research and development. Their R&D initiatives include:
- Exploring New Applications: The company is actively investigating additional therapeutic areas beyond their current offerings, seeking to unlock the potential of collagenase in treating various medical conditions that currently lack effective treatments.
- Clinical Trials: Biospecifics engages in clinical research to evaluate the safety and efficacy of their products in diverse patient populations. Ongoing trials help refine their formulations and explore optimal delivery methods.
- Patient Outcomes Improvement: The research team is dedicated to improving the overall treatment experience and outcomes for patients through innovative approaches that not only address the underlying conditions but also reduce the need for invasive procedures.
Conclusion
Overall, Biospecifics Technologies Corp offers a distinctive portfolio of products and services centered around injectable collagenase-based therapies for multiple medical conditions. With its flagship product XIAFLEX and a commitment to ongoing innovation, the company is positioned to make significant contributions to the biopharmaceutical industry and enhance patient care globally.
1. Medical / Pharmaceutical Products
At the forefront of Biospecifics Technologies Corps product lineup is XIAFLEX. This injectable collagenase enzyme represents a groundbreaking advance in the treatment of several conditions characterized by excessive collagen buildup. XIAFLEX acts by breaking down collagen, leading to tissue release and improved mobility in affected areas. Its key indications include:
- Dupuytrens Contracture: A hand condition that leads to the thickening and shortening of connective tissues, resulting in the fingers bending towards the palm, which can significantly hinder hand function. XIAFLEX works by enzymatically targeting and disrupting the collagen strands, allowing the fingers to be straightened.
- Peyronie’s Disease: A condition that results in the formation of fibrous scar tissue within the penis, causing curved, painful erections. XIAFLEX is administered via injection directly into the scar tissue, facilitating collagen breakdown and improving penile curvature and function.
- Cellulite: XIAFLEX is also employed in treating cellulite, a condition characterized by lumpy, dimpled skin, particularly on the thighs and buttocks. The injectable collagenase targets the fibrous bands beneath the skin, softening and releasing the tension, leading to smoother skin appearance.
In addition to XIAFLEX, Biospecifics Technologies Corp is actively engaged in the development of other collagenase-based therapies for additional conditions, including:
- Uterine Fibroids: These benign tumors of the uterus can cause pain and heavy menstrual bleeding. The company is exploring collagenase applications to alleviate symptoms and reduce the size of fibroids non-surgically.
- Adhesive Capsulitis (Frozen Shoulder): This painful condition restricts the shoulders range of motion. Research is underway to utilize collagenase injections to release the tight, thickened tissue surrounding the shoulder joint, providing pain relief and restoring mobility.
- Lipomas: Non-cancerous tumors composed of fat tissue that can be painful or bothersome. The application of collagenase has the potential to non-invasively diminish these growths.
Licensing and Collaborations
Biospecifics Technologies Corp is open to forming partnerships with other pharmaceutical companies and organizations that wish to leverage its expertise in collagenase-based therapies. Through licensing agreements, they provide their advanced drug development, clinical trial management, and regulatory experience to potential collaborators. This strategic collaboration model helps expand the reach of their innovative therapies and promotes the development of new applications addressing unmet medical needs.
Research and Development
Recognizing the changing landscape of medicine and the ongoing need for novel therapies, Biospecifics Technologies Corp is heavily invested in research and development. Their R&D initiatives include:
- Exploring New Applications: The company is actively investigating additional therapeutic areas beyond their current offerings, seeking to unlock the potential of collagenase in treating various medical conditions that currently lack effective treatments.
- Clinical Trials: Biospecifics engages in clinical research to evaluate the safety and efficacy of their products in diverse patient populations. Ongoing trials help refine their formulations and explore optimal delivery methods.
- Patient Outcomes Improvement: The research team is dedicated to improving the overall treatment experience and outcomes for patients through innovative approaches that not only address the underlying conditions but also reduce the need for invasive procedures.
Conclusion
Overall, Biospecifics Technologies Corp offers a distinctive portfolio of products and services centered around injectable collagenase-based therapies for multiple medical conditions. With its flagship product XIAFLEX and a commitment to ongoing innovation, the company is positioned to make significant contributions to the biopharmaceutical industry and enhance patient care globally.